Phase 3 Myeloma Trial, Recruiting (NCT07202052)

Phase 3 Myeloma Trial, Recruiting NCT07202052 Sponsor: Monash University Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT07202052 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed with a blood cancer, specifically chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), or non-Hodgkin's lymphoma (NHL)
People whose treating doctor has determined them eligible for immunoglobulin (Ig) replacement therapy — given through a vein or under the skin — due to a history of frequent or serious infections and low immunoglobulin G (IgG) levels in their blood
People with a life expectancy of more than 12 months
People who are able to understand and agree to take part in the trial (give informed consent)

Who may not be able to join:

People whose treating medical team considers that joining the study would not be in the patient's best interests

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zoe McQuilten, Professor, Monash University

Australian sites

Royal Adelaide Hospital, Adelaide, South Australia
+61 (8) 7074 5898

Austin Hospital, Melbourne, Victoria
+61 (03) 9070 5741

Northern Health, Melbourne, Victoria
+61 (03) 8408 6000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07202052

Sponsor: Monash University

Phase: Phase 3

Status: Recruiting

Condition: Myeloma

More information: https://clinicaltrials.gov/study/NCT07202052

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed with a blood cancer, specifically chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), or non-Hodgkin's lymphoma (NHL)
People whose treating doctor has determined them eligible for immunoglobulin (Ig) replacement therapy — given through a vein or under the skin — due to a history of frequent or serious infections and low immunoglobulin G (IgG) levels in their blood
People with a life expectancy of more than 12 months
People who are able to understand and agree to take part in the trial (give informed consent)

Who may not be able to join:

People whose treating medical team considers that joining the study would not be in the patient's best interests

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Monash University

Registry

ClinicalTrials.gov

Start date

6 May 2025

Est. completion

31 March 2027

Where this trial is recruiting

🇦🇺 Australia

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Event-free survival (EFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov